Page 94 - CIBEREHD2016-ENG

LEAD rESEArCHEr
Lanas Arbeloa, Ángel
Instituto Aragonés de Ciencias de la Salud
Hospital Clínico Universitario Lozano Blesa
Avda. San Juan Bosco 13 50009 Zaragoza
(+34) 976 76 57 86 [email protected] group Website
GROUP MEMBERS
Staff members: Arechavaleta Tabuenca, Samanta Pilar | Chueca Lapuente, Eduardo
Associated members: Abián Franco, Olga | Arroyo Villarino, María Teresa | Baptista, Pedro Miguel | Benito Ruesca, Rafael | Casado Arroyo, Rubén | Fernández Arenas, Ángel | García González, María Asunción | Gomollón García, Fernando | Ortego Fernández de Retana, Francisco Javier | Piazuelo Ortega, Elena | Roncalés Lázaro, Pilar | Sopeña Biarge, Federico | Sostres Homedes, Carlos | Strunk Groot, Mark
Main lines of research
• Diseases of the digestive tract associated with acid inhibition of COX or H. Pylori infection. Identification of environmental and genetic risk factors for injuries and complications of gastro-intestinal mucosa, development of prevention and treatment strategies. • Biological and molecular mechanisms of neoplastic progression in Barrett’s esophagus: identification of new biomarkers and therapeutic targets for chemoprevention. • Identification of effective bactericide compounds against Helicobacter pylori infection.
• Genetic and environmental determinants involved on inflammatory or tumour processes of the digestive tract.
Genetic susceptibility and Helicobacter pylori infection associated with the development and prognosis of gastric cancer. • Study of the genetic basis of susceptibility to hereditary and familial colon cancer. • Diagnostic and Therapeutic Targets.
• Stem cells and cell therapy for different digestive and liver gastrointestinal diseases. Identification, separation and molecular characterization of cancer stem cells in esophageal cancer.
• Optimization of isolation and culture of human hepatocytes to be used for cell therapy source. Investigation of the role of bone marrow stem cells in liver regeneration in different human models of disease. • Bioengineering of organs and tissues (hepatic and pancreatic). Cellular therapies are being developed in patients, in a clinic level just like expansion of human stem cells of fetal and adult liver.
• Identification of bioactive compounds against protein targets related with digestive pathologies. Transport and selective release by using multifunctional nanoparticles and nanosphere/nanoaggregated polymers • Selected targets are associated with colon cancer (BFT), pancreatic cancer (NUPR1), Clostridium difficile infection (DPC) and viral hepatitis C (HCV NS3 protease). We work with gold nanoparticles (NP) as nanospheres /nanoclusters of polymers for drug transport and release.
94
PROGRAMMES
P2 | P4